NCT06736704 - SNV4818 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Solid Tumors

Interventions

DRUG

SNV4818

SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.

DRUG

Fulvestrant

Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)

Trial Locations (11)

2031

RECRUITING

Scientia Clinical Research, Randwick

2050

RECRUITING

Chris O'Brien Lifehouse, Camperdown

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

3168

RECRUITING

Monash Health, Clayton

6009

RECRUITING

Linear Clinical Research, Nedlands

19107

RECRUITING

Thomas Jefferson University-Sidney Kimmel Cancer Center, Philadelphia

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

77030

RECRUITING

The University of Texas M.D. Anderson Cancer Center, Houston

02114

RECRUITING

Massachusetts General Hospital, Boston

K1H 8L6

RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

RECRUITING

University Health Network, Princess Margaret Cancer Centre, Toronto